Recurrence Risk Reduced With AI vs Tamoxifen in Premenopausal ER+ Breast Cancer
This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.
San Antonio Breast Cancer Symposium (SABCS)
Genomic-Based Targeted Therapy Improved PFS for Certain Metastatic Breast Cancers
The researchers found that targeted therapies matched to genomic alterations in ESCAT tier I/II significantly improved progression-free survival.
Final Analysis of PALLAS Shows No Benefit With Palbociclib Plus Endocrine Therapy in Early Breast Cancer
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
Outcomes in Inflammatory Breast Cancer Improved With Modern Treatment
Researchers evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.
KEYNOTE-355 Identifies PD-L1 Expression Cutoff for Pembrolizumab Benefit in mTNBC
A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy.
Immune-Enriched Phenotype Linked to Improved TNBC Survival After AC
Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.
Nivolumab-Abemaciclib-Endocrine Therapy Trial Stopped Due to Toxicity
Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.
Preoperative Pembrolizumab Plus Radiotherapy Found Active in TNBC
Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.
Oncolytic Virus Primes an Immune Response in Breast Cancer
The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.
Promising Outcomes With Lenvatinib Plus Pembrolizumab in Advanced TNBC
The majority of responses seen were ongoing at data cutoff.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SABCS 2020 Immunotherapy In-depth
Loading... 
Loading...